These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 15996972)
1. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972 [TBL] [Abstract][Full Text] [Related]
2. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977 [TBL] [Abstract][Full Text] [Related]
4. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]
7. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Slish J; Ma Q; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau D; Boston NS; Catanzaro L; DiFrancesco R; Morse GD Ther Drug Monit; 2007 Oct; 29(5):560-5. PubMed ID: 17898644 [TBL] [Abstract][Full Text] [Related]
8. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors. Sahloff EG; Duggan JM Ann Pharmacother; 2006 Oct; 40(10):1731-6. PubMed ID: 16968825 [TBL] [Abstract][Full Text] [Related]
11. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877 [TBL] [Abstract][Full Text] [Related]
13. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir. Moltó J; Deig E; Valle M; Maria Llibre J; Miranda C; Cedeño S; Valero S; Negredo E; Clotet B Ther Drug Monit; 2010 Feb; 32(1):93-6. PubMed ID: 20040897 [TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112 [TBL] [Abstract][Full Text] [Related]
15. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448 [TBL] [Abstract][Full Text] [Related]
16. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. Naeger LK; Struble KA AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968 [TBL] [Abstract][Full Text] [Related]
17. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. de Lastours V; Ferrari Rafael De Silva E; Daudon M; Porcher R; Loze B; Sauvageon H; Molina JM J Antimicrob Chemother; 2013 Aug; 68(8):1850-6. PubMed ID: 23599359 [TBL] [Abstract][Full Text] [Related]
18. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709 [TBL] [Abstract][Full Text] [Related]
19. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study. Keiser PH; Nassar N Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047 [TBL] [Abstract][Full Text] [Related]